Head-to-Head

Arcutis Biotherapeutics, Inc. Common Stock vs. Johnson & Johnson

ARQT

Arcutis Biotherapeutics, Inc. Common Stock

$24.25 +1.53%

VS JNJ

Johnson & Johnson

$269.47 -0.19%

Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 9 compared factors.

Size & Scale

ARQTJNJ
Market Cap $3.00 billion $650.65 billion
Revenue (TTM) $463.98 million $97.93 billion
Net Income (TTM) $28.52 million $21.04 billion

JNJ leads on 3 of 3 size & scale factors.

Valuation

ARQTJNJ
P/E Ratio 115.48 31.26
Price / Book 13.61 7.66
Price / Sales 6.47 6.64

JNJ leads on 2 of 3 valuation factors.

Profitability

ARQTJNJ
Net Margin 6.15% 21.48%
Return on Equity 12.93% 24.76%

JNJ leads on 2 of 2 profitability factors.

Dividend

ARQTJNJ
Dividend Yield — 1.99%
Payout Ratio — 62.18

ARQT and JNJ split the dividend factors evenly.

Risk & Sentiment

ARQTJNJ
Short Interest 0.19% 0.67%

ARQT leads on 1 of 1 risk & sentiment factors.

Dig deeper: ARQT overview, ARQT financials, JNJ overview, JNJ financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.